PTC Therapeutics, Inc.
PTCT
$50.57
$1.653.37%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -84.79% | 451.71% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -84.79% | 451.71% | |||
| Cost of Revenue | 2.11% | -13.62% | |||
| Gross Profit | -94.83% | 1,361.84% | |||
| SG&A Expenses | 5.31% | -4.40% | |||
| Depreciation & Amortization | 6.92% | 14.85% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.46% | -9.80% | |||
| Operating Income | -103.60% | 6,208.64% | |||
| Income Before Tax | -107.64% | 1,081.88% | |||
| Income Tax Expenses | -109.80% | 319.57% | |||
| Earnings from Continuing Operations | -107.48% | 1,415.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -107.48% | 1,415.24% | |||
| EBIT | -103.60% | 6,208.64% | |||
| EBITDA | -102.79% | 10,824.97% | |||
| EPS Basic | -107.48% | 1,399.89% | |||
| Normalized Basic EPS | -107.61% | 1,981.70% | |||
| EPS Diluted | -108.27% | 1,276.47% | |||
| Normalized Diluted EPS | -108.42% | 1,782.40% | |||
| Average Basic Shares Outstanding | 0.05% | 1.18% | |||
| Average Diluted Shares Outstanding | -9.53% | 11.90% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||